Quantcast

Latest SMN2 Stories

2014-11-19 08:28:48

- PTC Therapeutics to Receive $10 Million Milestone Payment from Roche - SOUTH PLAINFIELD, N.J., Nov. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc.

2014-08-07 16:27:47

-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J., Aug.

2010-12-15 06:00:00

WALTHAM, Mass., Dec. 15, 2010 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA").

2010-07-12 13:26:46

The devastating, currently incurable motor-neuron disease spinal muscular atrophy (SMA) might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides (ASOs).

2009-11-04 15:00:26

A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants.

5258660def903a7f555ee9e20aa9349b1
2009-07-28 09:40:00

Spinal Muscular Atrophy is the second-leading cause of infant mortality in the world.


Word of the Day
obdormition
  • Sleep; the state or condition of being asleep.
  • The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.
The word 'obdormition' comes from a Latin word meaning "to fall asleep".
Related